Supriya Lifescience share price rallied 20% during Friday’s trading session after the company posted a strong set of Q4 FY26 earnings. The rally was driven by strong revenue growth, improved operational efficiency, and steady demand from export markets.
The stock also witnessed a sharp rise in trading volumes, indicating strong investor interest.
The company delivered a robust performance in Q4 FY26, with net profit rising 47% YoY to ₹74.23 crore compared to ₹50.37 crore in the same quarter last year.
Revenue from operations grew 50.2% YoY to ₹276.53 crore, up from ₹184.11 crore in Q4 FY25, driven by strong demand across key therapeutic segments and steady growth in regulated export markets.
EBITDA for the quarter also improved significantly, increasing to ₹97.62 crore from ₹67.58 crore in the year-ago period, reflecting better operating leverage and improved efficiency.
During FY26, revenue from operations rose 18.9% YoY to ₹827.87 crore compared to ₹696.48 crore in FY25.
EBITDA increased 12.8% to ₹294.05 crore from ₹260.79 crore, while net profit grew 11.3% YoY to ₹209.12 crore versus ₹187.96 crore in the previous year.
The growth was largely supported by strong performance in the anaesthetic segment, along with increasing traction in newly launched cardiovascular and ADHD-related products.
Satish Wagh, Executive Chairman and Whole Time Director of Supriya Lifescience, said the strong quarterly and annual performance was driven by healthy demand across key therapeutic areas, solid traction in regulated markets, and consistent operational execution.
He also added that the company remains focused on strengthening manufacturing capabilities, backward integration, innovation, and expanding finished dosage forms for long-term sustainable growth.
As of May 29, 2026, Supriya Lifescience share price surged 20% and hit the upper circuit as well as a 52-week high, supported by a sharp volume jump of more than 12 times on the BSE. Finally, the shares closed the trading session at ₹968.70 apiece.
The company’s market capitalisation stands at ₹7,796.37 crore. Over the past one year, the stock has delivered returns of around 29% to investors.
The strong Q4FY26 performance led to a sharp rally in the shares of Supriya Lifescience, reflecting improved earnings visibility and sustained demand across key therapeutic segments. Going ahead, continued expansion in regulated markets and capacity enhancements are likely to remain key factors to watch.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 29, 2026, 4:49 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
